Loading…
Employees: 1,196
Size Shanghai Shenqi Pharmaceutical Investment Management (600613.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $483M, the 3932nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥6.40 on 6 Nov 2026.
Performance Over six months the shares gained 8.8%, against -18.1% for the median peer and -16.4% for the China market (cap-weighted) — 4th highest of 19 in its peer set.
Growth Revenue fell 4.0% over the last twelve months (peer median -5.2%); the operating margin is 2.6% (peer median 4.0%).
Valuation It trades at 1.4× enterprise value to sales against a peer median of 4.5× (5th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.8 points below its cost of capital (9.7% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.80B | CN¥1.94B | CN¥2.02B | CN¥2.31B | CN¥2.36B |
| Revenue growth | — | -4% | -13% | -2% | — |
| Gross profit | CN¥825M | CN¥838M | CN¥919M | CN¥1.11B | CN¥1.20B |
| EBITDA | n/a | CN¥156M | CN¥187M | CN¥232M | CN¥170M |
| Net income | CN¥8.65M | CN¥38.2M | CN¥71.4M | CN¥57.0M | CN¥48.5M |
| Free cash flow | CN¥223M | CN¥94.1M | CN¥172M | CN¥192M | CN¥294M |
| Capital expenditure | CN¥18.1M | CN¥33.2M | CN¥36.4M | CN¥24.5M | CN¥26.6M |
| Total debt | CN¥71.1M | CN¥348M | CN¥264M | CN¥406M | CN¥508M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600613.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -21.9% | -11.3% | 2nd lowest of 20 |
| 6-month return | +8.8% | -18.1% | 4th highest of 19 |
| Distance from 52-week high | -49.9% | -37.9% | 4th lowest of 20 |
| Revenue growth (TTM) | -4.0% | -5.2% | 9th highest of 20 |
| Operating margin | 2.6% | 4.0% | 10th lowest of 20 |
| EV / Sales | 1.4× | 4.5× | 5th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 13.4% | -0.4% | 3rd most demanding of 9 |
| Growth delivered (Del g) | +1.4% | +0.9% | 4th highest of 9 |
| Hurdle (Req g minus delivered) | +12.0 pp | -1.6 pp | 3rd most demanding of 9 |
| ROIC minus cost of capital | -4.8 pp | -2.5 pp | 9th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Shenqi Pharmaceutical Investment Management 600613.SS | China | $483M | +9% | -4% | 3% | 1.4× | 13.4% | +1.4% |
| Alpha Teknova TKNO | United States | $482M | +104% | +12% | -35% | 11.3× | n/a | n/a |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $484M | -23% | -14% | 12% | 0.5× | -18.6% | +6.3% |
| Daewoong 003090.KS | South Korea | $485M | -29% | +5% | 11% | 0.9× | n/a | n/a |
| CytomX Therapeutics CTMX | United States | $477M | -45% | -87% | -477% | 8.3× | n/a | n/a |
| Elixiron Immunotherapeutics (Cayman) 7871.TWO | Taiwan | $477M | +62% | +10,947% | -194% | 132.2× | n/a | n/a |
| PKU Healthcare 000788.SZ | China | $489M | -11% | -49% | 5% | 2.5× | -2.6% | -5.6% |
| Electra Therapeutics ETRA | United States | $490M | n/a | n/a | n/a | n/a | n/a | n/a |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $476M | -10% | +40% | 13% | 11.1× | 44.5% | +1.0% |
| Jiangsu Sihuan Bioengineering 000518.SZ | China | $476M | +7% | -17% | -28% | 11.5× | n/a | n/a |
| Pulike Biological Engineering 603566.SS | China | $475M | -22% | -9% | 5% | 2.5× | 5.7% | +3.3% |
| YungShin Global 3705.TW | Taiwan | $474M | +7% | -8% | 15% | 1.9× | -4.9% | +0.7% |
| Cachet Pharmaceutical 002462.SZ | China | $471M | -22% | -14% | 0% | 0.2× | -8.9% | -3.4% |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $495M | -16% | +23% | -61% | 19.6× | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $495M | +18% | +10% | 15% | 5.2× | n/a | n/a |
| Kexing Biopharm 688136.SS | China | $470M | -38% | -14% | -12% | 3.1× | n/a | n/a |
| Zhejiang Huakang Pharmaceutical 605077.SS | China | $470M | -39% | +35% | 4% | 1.2× | n/a | n/a |
| Cheng Du Sheng Nuo Biotec 688117.SS | China | $496M | -44% | +51% | 27% | 3.9× | 1.7% | +14.5% |
| Harbin Medisan Pharmaceutical 002900.SZ | China | $467M | -13% | -5% | -29% | 4.5× | n/a | n/a |
| Evonile Pharma EVONILE.NS | India | $466M | n/a | -5% | 12% | 14.5× | 46.5% | -1.5% |
| Shaanxi Kanghui Pharmaceutical Co 603139.SS | China | $466M | -20% | -21% | -68% | 9.0× | n/a | n/a |